Here’s How Much You Would Have Made Owning Insmed Stock In The Last 5 Years
Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance
Insmed to Present at November and December 2026 Investor Conferences
HC Wainwright & Co. Assumes Insmed at Buy, Announces Price Target of $220
Guggenheim Maintains Buy on Insmed, Lowers Price Target to $201
Insmed (INSM) Lifts Guidance After Earnings As Fair Value Debate Heats Up
Insmed (INSM) Begins BRINSUPRI Sales In Japan
Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript
What Insmed (INSM) Said on Its Q3 Earnings Call
Insmed (INSM) Q3 2026 Earnings Call Transcript
Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed: Q3 Earnings Snapshot
Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update
Insmed Incorporated 2026 Q3 - Results - Earnings Call Presentation
Insmed Q3 EPS $(0.46) Misses $(0.43) Estimate, Sales $524.428M Beat $501.350M Estimate
Insmed Raises FY2026 Sales Guidance from $1.700B-$1.870B to $1.810B-$1.870B vs $1.801B Est
$100 Invested In Insmed 15 Years Ago Would Be Worth This Much Today
Insmed (INSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Morgan Stanley Maintains Overweight on Insmed, Lowers Price Target to $213
Insmed Launches BRINSUPRI® Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.